Rizatriptan Benzoate Tablet
Product Images NDC 82804-202

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Rizatriptan Benzoate (NDC 82804-202). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Proficient Rx Lp, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

82804-202-12 (E7414f2d D7cf 41e5 B457 F5850e8bb7a7 00)

82804-202-12 (E7414f2d D7cf 41e5 B457 F5850e8bb7a7 00)
Label for Rizatriptan Benzoate 10 mg tablets from Proficient Rx LP. The package contains 12 pale pink, circular, flat, beveled-edge, uncoated tablets marked with 'X' on one side and '14' on the other. Manufactured for Rising Health, LLC, made in India, with storage instructions of 20°-25°C.*
FDA Label Image

Figure 1: Estimated Probability Of Achieving An Initial Headache Response By 2 Hours In Pooled Studies 1, 2, 3, And 4†† (Rizatriptan Fig1)

Figure 1: Estimated Probability Of Achieving An Initial Headache Response By 2 Hours In Pooled Studies 1, 2, 3, And 4†† (Rizatriptan Fig1)
A Kaplan-Meier plot showing the estimated probability of achieving an initial headache response by 2 hours post-dose. The graph compares placebo, Rizatriptan Benzoate 5 mg, and Rizatriptan Benzoate 10 mg in pooled data from four placebo-controlled outpatient trials. The x-axis represents hours post-dose (0 to 2 hours), and the y-axis represents the estimated probability of response (0% to 100%). Rizatriptan Benzoate 10 mg shows the highest probability of response over time.*
FDA Label Image

Figure 2: Estimated Probability Of Patients Taking A Second Dose Of Rizatriptan Benzoate Tablets Or Other Medication For Migraines Over The 24 Hours Following The Initial Dose Of Study Treatment In Pooled Studies 1, 2, 3, And 4††† (Rizatriptan Fig2)

Figure 2: Estimated Probability Of Patients Taking A Second Dose Of Rizatriptan Benzoate Tablets Or Other Medication For Migraines Over The 24 Hours Following The Initial Dose Of Study Treatment In Pooled Studies 1, 2, 3, And 4††† (Rizatriptan Fig2)
Kaplan-Meier plot showing the estimated probability over 24 hours of patients taking a second dose of Rizatriptan Benzoate tablets (5 mg and 10 mg) or other medication for migraines compared to placebo. The graph tracks the cumulative probability of remedication or rescue by hours post-dose, based on pooled clinical study data.*
FDA Label Image

Figure 5: Observed Percentage Of Patients Reporting No Headache Pain By 2 Hours Post-dose In Study 7 (Rizatriptan Fig3)

Figure 5: Observed Percentage Of Patients Reporting No Headache Pain By 2 Hours Post-dose In Study 7 (Rizatriptan Fig3)
Line graph depicting the observed percentage of patients reporting no headache pain within 2 hours after dosing in a clinical study. The graph compares Rizatriptan Benzoate Orally Disintegrating Tablets with placebo over time intervals from 0.5 to 2 hours post-dose, showing a higher percentage of pain-free patients in the Rizatriptan group.*
FDA Label Image

Chemical Structure (Rizatriptan Str)

Chemical Structure (Rizatriptan Str)
Chemical structure of Rizatriptan Benzoate, showing the molecular arrangement of atoms in the compound including a phenyl ring with a carboxyl group and a triazole-containing bicyclic structure.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.